Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.55 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.48 |
| ▸ | DGAT1 | O75907 | 7/20 | 0.47 |
| ▸ | VNN1 | O95497 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.42 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4927632 | 0.80 | L3MBTL1 (0.53) | CNR2SCN9ADGAT1VNN1SPHK2 | |
| SCHEMBL4927636 | 0.80 | L3MBTL1 (0.53) | CNR2SCN9ADGAT1VNN1SPHK2 | |
| SCHEMBL4928498 | 0.78 | DPP4 (0.51) | CNR2SCN9ADGAT1VNN1PIK3CA | |
| SCHEMBL4928499 | 0.78 | DPP4 (0.51) | CNR2SCN9ADGAT1VNN1PIK3CA | |
| SCHEMBL13570410 | 0.76 | CNR2 (0.53) | CNR2SCN9ASPHK2 | |
| SCHEMBL5909207 | 0.76 | CNR2 (0.48) | CNR2SCN9AVNN1 | |
| SCHEMBL5909210 | 0.76 | CNR2 (0.48) | CNR2SCN9AVNN1 | |
| SCHEMBL13570373 | 0.75 | SCN9A (0.58) | CNR2SCN9AVNN1SPHK2SPHK1 | |
| SCHEMBL20811691 | 0.74 | CNR2 (0.47) | CNR2SCN9AVNN1PIK3CASPHK2 | |
| SCHEMBL2999679 | 0.74 | CNR2 (0.50) | CNR2SCN9AVNN1PIK3CASPHK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190773-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-29 | — | — | US | claimed |
| US-20060276496-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276496-A1 | Anti-Cytokine Heterocyclic Compounds | MAPKAPK2, MAP4K2, MAP3K2 | CNR2 1935/4885SCN9A 3630/4885DGAT1 2575/4885 |
| US-20100190773-A1 | Anti-Cytokine Heterocyclic Compounds | MAPKAPK2, MAP4K2, MAP3K2 | CNR2 1935/4885SCN9A 3630/4885DGAT1 2575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.